UBS AM’s Bicara Therapeutics BCAX Stock Holding History

UBS AM’s Portfolio BCAX Stock Details BCAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$725K	Buy	24,425 +23,815	+3,904%	+$531K	﹤0.01%	2437
2026 Q1	$12.1K	Buy	610 +534	+703%	+$9.19K	﹤0.01%	3267
2025 Q4	$1.28K	Buy	+76	New	+$1.3K	﹤0.01%	3162

Other funds holding BCAX

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

RTM

Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS AM's BCAX Position: Q2 2026 in Review

UBS AM increased its Bicara Therapeutics (BCAX) stake by 3,904% in Q2 2026, buying an estimated $531K and bringing the position to 24,425 shares worth $725K. The position accounts for ﹤0.01% of the portfolio, ranked #2437.

UBS AM first reported a position in BCAX in Q4 2025 and has held it in 3 quarters since. 170 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

UBS AM held 24,425 shares of Bicara Therapeutics worth $725K as of Q2 2026.
UBS AM bought 23,815 Bicara Therapeutics shares in Q2 2026, an estimated $531K.
Bicara Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #2437 holding.
UBS AM first reported a position in Bicara Therapeutics in Q4 2025 and has held it in 3 quarters since.
170 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.